Komori
Other Disclosures4884Kringle Pharma,Inc.Pharmaceuticals

Kinjo Kazuki (金城一貴), our Head of Corporate Strategy Office, will speak at the Regenerative Medicine Leading Scientist Session Vol. 2.

At a regenerative medicine-related event to be held on 6 August 2026, our Head of Corporate Strategy is scheduled to speak about the potential of HGF in the field of regenerative medicine.

Worth reading
46Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Announced details

HGF (hepatocyte growth factor) protein drug
Applicable field (uses covered by this announcement)

Regenerative medicine and research and development of treatments for intractable diseases

Launch date6 August 2026 (scheduled speaking engagement and event date)
Relationship between the counterparty and the company
Kringle Pharma,Inc.4884
Relationship with the Company

Our Head of Corporate Strategy will speak at an event organized by the organization. Details of the capital, personnel and business relationships are not disclosed.

CounterpartyGeneral Incorporated Association LINK-J

Organizer of the Regenerative Medicine Leading Scientist Session Vol. 2. Other information on its location, representative, business activities, capital and year of establishment is not disclosed.

Location (as indicated in this announcement)

Mitsui Link Lab Nakanoshima conference room (3rd floor, Nakanoshima Qross, 4-3-51 Nakanoshima, Kita-ku, Osaka)

Capacity: 50 people
Offering price

Free of charge

The company does not address Contract Value / Impact on Business Performance.

Source (materials cited by the company)

LINK-J event page (https://www.link-j.org/event/article-52415.html)

Announced details
ItemDetails
Names of Products / Services CoveredHGF (hepatocyte growth factor) protein drug
CounterpartyGeneral Incorporated Association LINK-J
Counterparty overviewOrganizer of the Regenerative Medicine Leading Scientist Session Vol. 2. Other information on its location, representative, business activities, capital and year of establishment is not disclosed.
Relationship with the CompanyOur Head of Corporate Strategy will speak at an event organized by the organization. Details of the capital, personnel and business relationships are not disclosed.
Offering priceFree of charge
Launch date6 August 2026 (scheduled speaking engagement and event date)
Applicable areaRegenerative medicine and research and development of treatments for intractable diseases
LocationMitsui Link Lab Nakanoshima conference room (3rd floor, Nakanoshima Qross, 4-3-51 Nakanoshima, Kita-ku, Osaka)
Location scaleCapacity: 50 people
SourceLINK-J event page (https://www.link-j.org/event/article-52415.html)
Items this document does not state (8)
Contract ValueContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateQuantitative EffectsUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Through the presentation at an event introducing cutting-edge research trends and insights into practical applications in regenerative medicine, as well as innovative initiatives, to provide participants with an opportunity to deepen their understanding of the latest research and business trends.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Kinjo Kazuki (金城一貴), our Head of Corporate Strategy Office, will speak at the Regenerative Medicine Leading Scientist Session Vol. 2. | Kringle Pharma,Inc. (4884) timely disclosure | Komori